bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

28 May 2024 18:01 CEST

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1257721_PR_bioMrieux_VIDAS_TBI_FDA_Clearance_20240528.pdf